Clinical Trial Update: Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating hemostatic effects of VELCADE treatment in patients with multiple myeloma; study terminated with posted results in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: University of Utah | Conditions: Multiple Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2017-07-07